Edwards v. CoreValve
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences files transcatheter heart valve patent suit against competitor CoreValve in the District Court of Dusseldorf, Germany May 10. Edwards, developer of the Sapien transcatheter aortic valve, says it has an exclusive sublicense to the patent in question from Johnson & Johnson/Heartport. Edwards, which anticipates European commercialization of Sapien by year-end, is discussing a possible licensing arrangement with CoreValve, which had hoped to launch its ReValving transcatheter aortic valve in Europe in early 2007. Edwards recently received FDA go-ahead to begin a trial to support approval of its device in the United States (1"The Gray Sheet" March 26, 2007, p. 10)...
You may also be interested in...
CoreValve gets CE mark
Firm will not immediately launch its ReValving percutaneous aortic valve following European clearance announced May 16 for high-risk patients. Instead, an expanded clinical evaluation at selected centers will focus on physician training, appropriate patient selection and gathering clinical feedback, the firm says. It expects data from a mandatory patient registry to help support FDA go-ahead to start a clinical trial for the device in the United States. Competitor Edwards Lifesciences, which received FDA approval for a U.S. trial in March, expects CE mark later this year for its Sapien transcatheter aortic valve. The firm recently filed a patent suit against CoreValve in Germany (1"The Gray Sheet" May 14, 2007, In Brief)...
Edwards Set To Launch “Two-Trials-In-One” For Sapien Percutaneous Valve
Edwards Lifesciences will soon begin a 600-patient U.S. pivotal clinical trial for its Sapien transcatheter aortic replacement heart valve at Columbia University Medical Center and the Cleveland Clinic, the company says
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.